These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37984242)

  • 21. Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis.
    Travaglino A; Raffone A; Santoro A; Raimondo D; Angelico G; Valente M; Arciuolo D; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Seracchioli R; Zannoni GF
    Gynecol Oncol; 2021 Sep; 162(3):804-808. PubMed ID: 34266691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype.
    Huvila J; Thompson EF; Vanden Broek J; Lum A; Senz J; Leung S; Gilks CB; Köbel M; McAlpine JN; Jamieson A
    Histopathology; 2023 Dec; 83(6):880-890. PubMed ID: 37580913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
    Krämer P; Talhouk A; Brett MA; Chiu DS; Cairns ES; Scheunhage DA; Hammond RFL; Farnell D; Nazeran TM; Grube M; Xia Z; Senz J; Leung S; Feil L; Pasternak J; Dixon K; Hartkopf A; Krämer B; Brucker S; Heitz F; du Bois A; Harter P; Kommoss FKF; Sinn HP; Heublein S; Kommoss F; Vollert HW; Manchanda R; de Kroon CD; Nijman HW; de Bruyn M; Thompson EF; Bashashati A; McAlpine JN; Singh N; Tinker AV; Staebler A; Bosse T; Kommoss S; Köbel M; Anglesio MS
    Clin Cancer Res; 2020 Oct; 26(20):5400-5410. PubMed ID: 32737030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
    Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
    J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
    Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
    Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
    Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
    J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification.
    Jamieson A; Thompson EF; Huvila J; Gilks CB; McAlpine JN
    Int J Gynecol Cancer; 2021 Jun; 31(6):907-913. PubMed ID: 33589443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
    Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
    Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reviving peritoneal cytology: Exploring its role in endometrial cancer molecular classification.
    Villiger AS; Zurbriggen S; Imboden S; Solass W; Christe L; Saner FAM; Gmür A; Rau TT; Mueller MD; Siegenthaler F
    Gynecol Oncol; 2024 Mar; 182():148-155. PubMed ID: 38266401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endometrial Cancer: Transitioning from Histology to Genomics.
    Mitric C; Bernardini MQ
    Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
    Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
    Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
    Loukovaara M; Bützow R; Staff S; Mäenpää M; Faltinová M; Lassus H; Veijalainen O; Grönvall M; Vaalavirta L; Kuikka E; Haataja M; Urpilainen E; Simojoki M; Anttila M; Auranen A
    Int J Gynecol Cancer; 2023 Nov; 33(11):1807-1811. PubMed ID: 37813479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).
    Li Y; Zhu C; Xie H; Chen Y; Lv W; Xie X; Wang X
    J Gynecol Oncol; 2023 Mar; 34(2):e37. PubMed ID: 36659832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incorporation of molecular characteristics into endometrial cancer management.
    Vermij L; Smit V; Nout R; Bosse T
    Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment options for molecular subtypes of endometrial cancer in 2023.
    Karpel HC; Slomovitz B; Coleman RL; Pothuri B
    Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
    Lindemann K; Kildal W; Kleppe A; Tobin KAR; Pradhan M; Isaksen MX; Vlatkovic L; Danielsen HE; Kristensen GB; Askautrud HA
    Eur J Cancer; 2024 Mar; 200():113584. PubMed ID: 38330767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
    Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
    Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia.
    Xue Y; Dong Y; Lou Y; Lv Q; Shan W; Wang C; Chen X
    J Gynecol Oncol; 2023 Jul; 34(4):e53. PubMed ID: 36929579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The influence of molecular classification in the selection of postoperative adjuvant therapy in endometrial carcinoma].
    Yan XS; Li M; Liang HM; Guo HY; Wu Y; He HJ; Zhang K; Li H
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(32):2500-2505. PubMed ID: 36008320
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular classification improves preoperative risk assessment of endometrial cancer.
    Cabrera S; Bebia V; López-Gil C; Luzarraga-Aznar A; Denizli M; Salazar-Huayna L; Abdessayed N; Castellví J; Colas E; Gil-Moreno A
    Gynecol Oncol; 2024 Oct; 189():56-63. PubMed ID: 39018900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.